請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/44658
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 莊曜宇(Eric Y. Chuang) | |
dc.contributor.author | Jo-Yang Lu | en |
dc.contributor.author | 呂若陽 | zh_TW |
dc.date.accessioned | 2021-06-15T03:52:26Z | - |
dc.date.available | 2013-07-16 | |
dc.date.copyright | 2010-07-16 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-07-08 | |
dc.identifier.citation | REFERENCE
1. Cancer Facts & Figures 2009. Atlanta: American Cancer Society2009. 2. 平成20年 人口動態統計(確定数)の概況: 厚生労働省保健統計課2009. 3. 98年度死因統計統計表: 行政院衛生署2010. 4. Bryant A, Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest. 2007 Jul;132(1):185-92. 5. Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst. 2010 Apr 7;102(7):464-74. 6. M. S. Tsao CZ, K. Ding, D. Strumpf, M. Pintilie, M. Meyerson, L. Seymour, I. Jurisica, F. A. Shepherd A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients. 2008 ASCO Annual Meeting2008. 7. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007 Jan 4;356(1):11-20. 8. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med. 2006 Aug 10;355(6):570-80. 9. Chang JT, Carvalho C, Mori S, Bild AH, Gatza ML, Wang Q, et al. A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell. 2009 Apr 10;34(1):104-14. 10. Carvalho CM, Chang J, Lucas JE, Nevins JR, Wang QL, West M. High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics. J Am Stat Assoc. 2008 Dec;103(484):1438-56. 11. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006 Jan 19;439(7074):353-7. 12. Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, Strumpf D, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol. 2007 Dec 10;25(35):5562-9. 13. The Molecular Signatures Database. Available from: http://www.broadinstitute.org/gsea/msigdb/index.jsp. 14. Dennis G, Jr., Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4(5):P3. 15. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000 May;25(1):25-9. 16. Ingenuity Pathways Analysis [database on the Internet]. Ingenuity Systems. Available from: http://www.ingenuity.com/. 17. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. 18. Tian L, Greenberg SA, Kong SW, Altschuler J, Kohane IS, Park PJ. Discovering statistically significant pathways in expression profiling studies. Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13544-9. 19. Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol. 2006 Apr 10;24(11):1679-88. 20. Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JM, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res. 2006 Aug 1;66(15):7466-72. 21. Cox DR. Regression Models and Life-Tables. Journal of the Royal Statistical Society Series B-Statistical Methodology. 1972;34(2):187-&. 22. Lee ES, Son DS, Kim SH, Lee J, Jo J, Han J, et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res. 2008 Nov 15;14(22):7397-404. 23. Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, Mitsudomi T, et al. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol. 2009 Jun 10;27(17):2793-9. 24. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008 Aug;14(8):822-7. 25. The R Project for Statistical Computing. Available from: http://www.r-project.org/. 26. Brunet JP, Tamayo P, Golub TR, Mesirov JP. Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4164-9. 27. Ebi H, Tomida S, Takeuchi T, Arima C, Sato T, Mitsudomi T, et al. Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses. Cancer Res. 2009 May 1;69(9):4027-35. 28. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002 Jan 31;415(6871):530-6. 29. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004 Feb;2(2):E7. 30. Semenza GL. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med. 2001 Aug;7(8):345-50. 31. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15623-8. 32. Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol. 2003;4(10):R69. 33. Welcsh PL, Lee MK, Gonzalez-Hernandez RM, Black DJ, Mahadevappa M, Swisher EM, et al. BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci U S A. 2002 May 28;99(11):7560-5. 34. Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, Wiltshire T, et al. Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4465-70. 35. Hallstrom TC, Mori S, Nevins JR. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell. 2008 Jan;13(1):11-22. 36. Mizuno H, Nakanishi Y, Ishii N, Sarai A, Kitada K. A signature-based method for indexing cell cycle phase distribution from microarray profiles. BMC Genomics. 2009;10:137. 37. Whitfield ML, George LK, Grant GD, Perou CM. Common markers of proliferation. Nat Rev Cancer. 2006 Feb;6(2):99-106. 38. Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, Sanchez JJ, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One. 2007;2(11):e1129. 39. Roninson IB. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 2002 May 8;179(1):1-14. 40. Liu Y, Yeh N, Zhu XH, Leversha M, Cordon-Cardo C, Ghossein R, et al. Somatic cell type specific gene transfer reveals a tumor-promoting function for p21(Waf1/Cip1). EMBO J. 2007 Nov 14;26(22):4683-93. 41. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006 Jun;9(6):425-34. 42. Dang CV, Lewis BC. Role of Oncogenic Transcription Factor c-Myc in Cell Cycle Regulation, Apoptosis and Metabolism. J Biomed Sci. 1997 Nov-Dec;4(6):269-78. 43. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18782-7. 44. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer. 2008 Dec;8(12):967-75. 45. Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN, et al. MYC regulation of a 'poor-prognosis' metastatic cancer cell state. Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3698-703. 46. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001 Feb 17;357(9255):539-45. 47. Schafer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol. 2008 Aug;9(8):628-38. 48. Gonda TA, Tu S, Wang TC. Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle. 2009 Jul 1;8(13):2005-13. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/44658 | - |
dc.description.abstract | 肺癌在全世界的已開發國家都是癌症死亡率之首。即使被分類為早期的肺癌患者,術後復發率也高達30%以上。雖然之前已有許多以檢測基因表現模式為基礎而開發的基因組,宣稱可被用於預測預後;但這些基因組之間重複性極低,使得直接應用這些基因組於臨床治療上的可行性令人疑慮。此外過去在建立預測預後基因組時,經常沒有考慮基因本身的生物意義或基因間的互動關係,使得這些預後基因組其整體生物意義通常是難以解讀的。
為了突破此一困境,我們提出一個全新的方法,同時整合了基因組顯著分析以及存活分析兩種技術。不但將篩選對象由單一基因改為事前由生物傳導途徑和生物實驗結果所定義的基因組,並藉由Cox風險迴歸模型來分析基因組的表現模式和存活結果的關係。這項整合使得結果不僅僅是具有預測病患存活結果能力的基因組,並且能展現生物現象及生物機能和存活結果之間相關性。 本方法由三個演算法所組成:第一步是以兩個虛無假說的檢驗來篩選和存活結果有關的基因組,兩個虛無假說在檢驗後皆被拒絕的基因組才進入下一步分析。第二步是以群集分析,將組成成員類似的基因組分入同組,並從每一組中選出一個做為代表性基因組。第三步是分析這些代表性基因組之間的基因表現模式相似程度,並把結果畫成基因組互動網路。 和肺腺癌預後相關的生物機能可以被分為四大類:和細胞週期調控有關、和細胞能量利用方式變異有關、和轉譯後修飾有關以及和傷口組織癒合有關幾個部分。雖然這些生物機能過去都曾經被文獻報導過,在肺腺癌的惡化過程中扮演了關鍵角色,我們的基因互動網路更顯示這些功能是藉由協同運作而達成促進癌症組織生長的結果。 我們的方法不僅可用於臨床上的預後預測,還可以檢驗任何連續性的資料以及基因組表現模式間的關係是否顯著。藉由同時引入事前定義的基因組和回歸分析,不但可檢定基因組的表現是否和資料有關,還可闡明和這些結果有關的生物意義為何。 | zh_TW |
dc.description.abstract | Lung cancer has been the leading cause of cancer related death worldwide. Hitherto, more than 30% of early stage lung cancer patients who received complete surgical resection died of relapse. Although lots of prognosis studies based on whole genome profiling had been published, little overlaps of the prognostic genes from different research groups made the utilization in clinical infeasible. Moreover, due to the biological meaning and the interactions of the prognostic genes were not taken into account in previous studies, explaining those results biologically and comprehensively was not easy.
To overcome the bottleneck, we proposed a novel method based on gene set enrichment analysis and Cox-hazard regression model. The predefined gene sets which derived from biological pathways, in vitro, and in vivo experiments were utilized as prognosis targets instead of single genes. Cox-hazard regression model was then applied to assess the relation between the survival outcome and the enrichment of gene sets. The integration of predefined gene sets and Cox-hazard regression model provided not only the power of predicting survival outcome, but also the connection between biological functions and prognosis. Our method was composed of three algorithms: first, a two-step hypothesis testing procedure was applied to select gene sets associated with the survival outcome. Second, prognostic genes sets were clustered, and a representative gene set was selected from each cluster. Lastly, the similarities between the gene expression patterns of those representative gene sets were evaluated by kernel matrix, and the results were illustrated as gene set association networks. The biological functions associated with the survival outcome of lung adenocarcinoma can be divided into four categories: cell cycle regulation, energy dysregulation, post-translation modification, and wound healing process. Although they were all reported by previous literatures as essential functions in the progression of lung adenocarcinoma, our data indicated that they functioned in a coordinate manner. Not only for clinical prognosis as we demonstrated, our method can also be applied to assess the relations between other types of continuous variable and gene set. By incorporating predefined gene sets and the regression model, the gene sets associated with the testing variables and the biological interpretation connected with those gene sets could be illuminated by our method. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T03:52:26Z (GMT). No. of bitstreams: 1 ntu-99-R97945003-1.pdf: 3427734 bytes, checksum: f4c56297bd4c6b2173c189c4fdb889ce (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | TABLE OF CONTENTS
謝誌 I 摘要 II ABSTRACT IV CHAPTER 1: INTRODUCTION 1 CHAPTER 2: LITERATURE REVIEW 6 2.1 CLASSICAL TRANSCRIPTOME DATA ANALYSIS 6 2.2 GENE SET ENRICHMENT ANALYSIS 7 2.3 STUDIES FOCUSED ON SURVIVAL OUTCOME OF NSCLC 9 CHAPTER 3: METHODOLOGY 11 3.1 GENERAL DESCRIPTION 11 3.2 EXPRESSION DATA PREPROCESSING 14 3.3 HYPOTHESIS TESTING FRAMEWORK 15 3.4 ASSIGNING GENE SET SCORE 18 3.5 CHOOSE REPRESENTATIVE GENE SETS FROM GENE SET CLUSTERS 20 3.6 THE ADJACENCY BETWEEN REPRESENTATIVE GENE SETS 22 3.7 VALIDATE PROGNOSTIC ABILITIES BY KAPLAN–MEIER ESTIMATOR 24 CHAPTER 4: RESULT 26 4.1 DATASETS USED IN THIS STUDY 26 4.2 GENE SETS USED IN THIS STUDY 27 4.3 GENERAL DESCRIPTION OF FINDING 28 4.4 REPRESENTATIVE GENE SETS SELECTED FROM THE CGP COLLECTION 30 CHAPTER 5: DISCUSSION 39 5.1 BIOLOGICAL FUNCTIONS RELATED TO THE PROGNOSIS GENE SETS 39 5.2 MERITS AND LIMITATIONS OF THIS METHOD 49 REFERENCE 52 A. APPENDIX 56 A.1 SUPPLEMENTARY TABLES AND FIGURES OF SECTION 4.4 56 A.2 REPRESENTATIVE GENE SETS SELECTED FROM THE BIOCARTA AND KEGG COLLECTION 62 A.3 REPRESENTATIVE GENE SETS SELECTED FROM THE GOBP COLLECTION 72 A.4 SUPPLEMENTARY TABLES OF DISCUSSION 84 REFERENCE OF APPENDIX 88 | |
dc.language.iso | en | |
dc.title | 以迴歸模型檢驗與肺腺癌預後相關之基因組 | zh_TW |
dc.title | Utilizing Cox Regression Model to Assess the Relations between Gene Sets and the Prognosis of Lung Adenocarcinoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蕭朱杏(Chuhsing Kate Hsiao),蔡孟勳(Mong-Hsun Tsai),賴亮全(Liang-chuan Lai),陳倩瑜(Chien-Yu Chen) | |
dc.subject.keyword | 非小細胞肺癌,預後,存活分析,基因組顯著性分析,事先定義之基因組, | zh_TW |
dc.subject.keyword | NSCLC,prognosis,survival analysis,functional enrichment,predefined gene set, | en |
dc.relation.page | 89 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2010-07-08 | |
dc.contributor.author-college | 電機資訊學院 | zh_TW |
dc.contributor.author-dept | 生醫電子與資訊學研究所 | zh_TW |
顯示於系所單位: | 生醫電子與資訊學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 3.35 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。